Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$391.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $36.0B · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$14.6B
P/E
0.0x
↓EV/EBITDA
-1.1x
↓ROE
6.1%
↑Gross Margin
43.0%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-12.8%
FCF CAGR
—
FCF margin
62.9%
FCF / Net income
1.49x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $69.42B · net income $29.35B · FCF $43.67B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $69.42B | $69.42B | $71.62B | $101.38B | $104.59B |
| Net Income | $29.35B | $29.35B | $7.53B | $5.98B | $5.10B |
| EBITDA | $53.99B | $53.99B | $31.51B | $31.75B | $23.77B |
| EPS | 11600.00 | 11600.00 | 46.00 | 48.00 | — |
| Gross Margin | 43.0% | 43.0% | 39.4% | 28.0% | 20.9% |
| Operating Margin | 27.2% | 27.2% | 10.0% | 6.2% | 4.3% |
| Net Margin | 42.3% | 42.3% | 10.5% | 5.9% | 4.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 79.84 | 79.84 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $43.67B | $43.67B | $31.60B | $35.98B | $-196.17B |
| Returns | |||||
| ROE | 6.1% | 6.1% | 1.8% | 1.4% | 1.4% |
| Valuation | |||||
| P/E | 0.03 | 0.03 | 33.04 | 52.50 | — |
| EV/EBITDA | -1.13 | -1.13 | 4.92 | 7.83 | 13.92 |
| P/B | 0.21 | 0.21 | 0.60 | 0.75 | 0.96 |
| Growth & Yield | |||||
| Revenue Growth | -3.1% | -3.1% | -29.4% | -3.1% | — |
| EPS Growth | 25117.4% | 25117.4% | -4.2% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-85.6%
EPS terminal req.
$34.69
Spread vs growth
25203.0%
5Y implied EPS CAGR
-67.5%
EPS terminal req.
$41.98
Spread vs growth
25184.9%
10Y implied EPS CAGR
-40.2%
EPS terminal req.
$67.61
Spread vs growth
25157.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.6%
Start / end P/E
12.6x → 0.0x
EPS bridge
46.00 → 11600.00
Residual
-25050.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.